Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
Authors:
Open Access
- 30 January 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1076421
Abstract
From the perspective of precision medicine, the challenge for the future is to improve the accuracy of diagnosis, prognosis, and prediction of therapeutic responses through the identification of biomarkers. In this framework, the omics sciences (genomics, transcriptomics, proteomics, and metabolomics) and their combined use represent innovative approaches for the exploration of the complexity and heterogeneity of multiple sclerosis (MS). This review examines the evidence currently available on the application of omics sciences to MS, analyses the methods, their limitations, the samples used, and their characteristics, with a particular focus on biomarkers associated with the disease state, exposure to disease-modifying treatments (DMTs), and drug efficacies and safety profiles.Keywords
This publication has 135 references indexed in Scilit:
- MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis PatientsInternational Journal of Molecular Sciences, 2013
- The clinical potential of blood-proteomics in multiple sclerosisBMC Neurology, 2013
- The discovery and development of belimumab: the anti-BLyS–lupus connectionNature Biotechnology, 2012
- Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility lociAnnals of Neurology, 2011
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Oxidative damage in multiple sclerosis lesionsBrain, 2011
- Sphingolipids in Multiple SclerosisNeuroMolecular Medicine, 2010
- Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scoreThe Lancet Neurology, 2009
- Inflammatory Multiple-Sclerosis Plaques Generate Characteristic Metabolic Profiles in Cerebrospinal FluidPLOS ONE, 2007
- Oxidative Stress Kills Human Primary Oligodendrocytes Via Neutral Sphingomyelinase: Implications for Multiple SclerosisJournal of Neuroimmune Pharmacology, 2007